Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1223466

Cover Image

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1223466

Global Kidney Cancer Diagnostics Market - Industry Trends and Forecast to 2030

PUBLISHED:
PAGES: 673 Pages
DELIVERY TIME: Inquiry
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License) - Printable/Downloadable
USD 4800
PDF (Enterprise License) - Printable/Downloadable
USD 7000

Add to Cart

Description

Table of Contents

List of Tables

Global Kidney Cancer Diagnostics Market is projected to register a CAGR of 6.4% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation

Global Kidney Cancer Diagnostics Market, By Test Type (Imaging, Biomarker Test, Blood Test, Biopsy, Genetic Test, and Others), Cancer Stages (Stage I , Stage II, Stage III, and Stage IV), Tumor Type (Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, and Non-Clear Cell Renal Cell Carcinoma), Product (Platform-Based Products, Instrument based products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research),End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Norway, Poland, Sweden, Belgium, Turkey, Denmark, Finland, Europe, China, Japan, India, Australia, New Zealand, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Taiwan and the rest of Asia-Pacific, South Africa, Saudi Arabia, Bahrain, UAE, Kuwait, Oman, Qatar, Egypt, Israel, the Rest of Middle East and Africa, Brazil, Argentina, and the Rest of South America), Industry Trends and Forecast to 2030.

.

Some of the major factors contributing to the growth of the kidney cancer diagnostics market are:

Rising healthcare expenditure for better health services

Rising Awareness about kidney cancer

Increase in diagnostic procedure for kidney cancer

Market Players

Some of the key market players for global kidney cancer diagnostics market are listed below:

Ambry Genetics

BD

BioVendor R&D

BluePrint Oy.

Canon Medical Systems Corporation

CD Genomics

CENTOGENE N.V.

Creative Diagnostics

FUJIFILM Corporation

GeneDx, LLC

GenPath

Grail

Illumina, Inc.

Invitae Corporation

Koninklijke Philips N.V.

Laboratory Corporation of America Holdings

Myriad Genetics, Inc.

Qiagen

Seimens Healthcare GmbH

Thermo Fisher Scientific Inc.

Show more

TABLE OF CONTENTS

1 INTRODUCTION 85

  • 1.1 OBJECTIVES OF THE STUDY 85
  • 1.2 MARKET DEFINITION 85
  • 1.3 OVERVIEW OF THE GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET 85
  • 1.4 CURRENCY AND PRICING 87
  • 1.5 LIMITATIONS 88
  • 1.6 MARKETS COVERED 88

2 MARKET SEGMENTATION 92

  • 2.1 MARKETS COVERED 92
  • 2.2 GEOGRAPHICAL SCOPE 93
  • 2.3 YEARS CONSIDERED FOR THE STUDY 94
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 95
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 98
  • 2.6 MULTIVARIATE MODELLING 99
  • 2.7 MARKET APPLICATION COVERAGE GRID 100
  • 2.8 TEST TYPE LIFELINE CURVE 101
  • 2.9 DBMR MARKET POSITION GRID 102
  • 2.10 VENDOR SHARE ANALYSIS 103
  • 2.11 SECONDARY SOURCES 104
  • 2.12 ASSUMPTIONS 104

3 EXECUTIVE SUMMARY 105

4 PREMIUM INSIGHTS 108

  • 4.1 PESTEL ANALYSIS 111
  • 4.2 PORTER'S 5 FORCES 112
  • 4.3 EPIDEMIOLOGY 113
    • 4.3.1 KIDNEY CANCER INCIDENCES, 2020, BY BOTH SEXES 114
    • 4.3.2 KIDNEY CANCER MORTALITY, 2020, BY BOTH SEXES 114

5 INDUSTRY INSIGHTS 115

6 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, REGULATIONS 117

7 MARKET OVERVIEW 120

  • 7.1 DRIVERS 122
    • 7.1.1 GROWING PREVALENCE OF KIDNEY CANCER 122
    • 7.1.2 INCREASE IN DIAGNOSTIC PROCEDURES FOR KIDNEY CANCER 124
    • 7.1.3 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 125
    • 7.1.4 RISING AWARENESS TOWARDS KIDNEY CANCER 125
  • 7.2 RESTRAINTS 126
    • 7.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF KIDNEY CANCER DIAGNOSTIC PRODUCTS 126
    • 7.2.2 TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS 127
  • 7.3 OPPORTUNITIES 127
    • 7.3.1 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 127
    • 7.3.2 GOVERNMENT INITIATIVES TOWARD KIDNEY CANCER DIAGNOSTICS 128
    • 7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE 128
    • 7.3.4 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS 129
  • 7.4 CHALLENGES 129
    • 7.4.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 129
    • 7.4.2 HIGH COST OF DIAGNOSTICS PROCEDURE FOR KIDNEY CANCERS 130

8 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE 131

  • 8.1 OVERVIEW 132
  • 8.2 IMAGING 136
    • 8.2.1 COMPUTED TOMOGRAPHY 137
    • 8.2.2 ULTRASOUND 137
    • 8.2.3 MAGNETIC RESONANCE IMAGING (MRI) 137
    • 8.2.4 ANGIOGRAPHY 137
    • 8.2.5 X-RAY 137
    • 8.2.6 OTHERS 137
  • 8.3 BLOOD TEST 137
  • 8.4 BIOPSY 138
    • 8.4.1 FINE NEEDLE ASPIRATION 139
    • 8.4.2 NEEDLE CORE BIOPSY 139
  • 8.5 BIOMARKER TEST 139
    • 8.5.1 AQUAPORIN 1 (AQP1) 141
    • 8.5.2 PERILIPIN (PLIN2) 141
    • 8.5.3 N-METHYLTRANSFERASE (NMNT) 141
    • 8.5.4 L-PLASTIN (LCP-1) 141
    • 8.5.5 NM23A 141
  • 8.6 GENETIC TEST 141
  • 8.7 OTHERS 142

9 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE 144

  • 9.1 OVERVIEW 145
  • 9.2 STAGE I 148
  • 9.3 STAGE II 148
  • 9.4 STAGE III 149
  • 9.5 STAGE IV 150

10 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE 151

  • 10.1 OVERVIEW 152
  • 10.2 RENAL CELL CARCINOMA 156
    • 10.2.1 IMAGING 157
    • 10.2.2 BLOOD TEST 157
    • 10.2.3 BIOPSY 157
    • 10.2.4 BIOMARKER TEST 157
    • 10.2.5 GENETIC TEST 157
    • 10.2.6 OTHERS 157
  • 10.3 CLEAR CELL RENAL CELL CARCINOMA 157
    • 10.3.1 IMAGING 159
    • 10.3.2 BLOOD TEST 159
    • 10.3.3 BIOPSY 159
    • 10.3.4 BIOMARKER TEST 159
    • 10.3.5 GENETIC TEST 159
    • 10.3.6 OTHERS 159
  • 10.4 NON CLEAR CELL RENAL CELL CARCINOMA 159
    • 10.4.1 PAPILLARY RENAL CELL CARCINOMA 160
      • 10.4.1.1 IMAGING 161
      • 10.4.1.2 BLOOD TEST 161
      • 10.4.1.3 BIOPSY 161
      • 10.4.1.4 BIOMARKER TEST 161
      • 10.4.1.5 GENETIC TEST 161
      • 10.4.1.6 OTHERS 161
    • 10.4.2 CHROMOPHOBE RENAL CELL CARCINOMA 161
      • 10.4.2.1 IMAGING 162
      • 10.4.2.2 BLOOD TEST 162
      • 10.4.2.3 BIOPSY 162
      • 10.4.2.4 BIOMARKER TEST 162
      • 10.4.2.5 GENETIC TEST 162
      • 10.4.2.6 OTHERS 162

11 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT 163

  • 11.1 OVERVIEW 164
  • 11.2 INSTRUMENT BASED PRODUCTS 168
    • 11.2.1 IMAGING 169
    • 11.2.2 BIOPSY 169
  • 11.3 PLATFORM BASED PRODUCTS 169
    • 11.3.1 NEXT GENERATION SEQUENCING 171
    • 11.3.2 MICROARRAYS 171
    • 11.3.3 PCR 172
    • 11.3.4 OTHERS 172
  • 11.4 KITS AND REAGENTS 172
    • 11.4.1 RENAL CANCER PANELS 174
    • 11.4.2 RENAL CANCER ANTIBODIES 174
  • 11.5 OTHER CONSUMABLES 174

12 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 175

  • 12.1 OVERVIEW 176
  • 12.2 FLUORESCENT IN SITU HYBRIDIZATION 179
  • 12.3 NEXT GENERATION SEQUENCING 179
  • 12.4 FLUORIMMUNOASSAY 180
  • 12.5 COMPARATIVE GENOMIC HYBRIDIZATION 181
  • 12.6 IMMUNOHISTOCHEMICAL 182
  • 12.7 OTHERS 182

13 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION 184

  • 13.1 OVERVIEW 185
  • 13.2 SCREENING 188
    • 13.2.1 INSTRUMENT BASED PRODUCTS 189
    • 13.2.2 PLATFORM BASED PRODUCTS 189
    • 13.2.3 KITS AND REAGENTS 189
    • 13.2.4 OTHER CONSUMABLES 189
  • 13.3 DIAGNOSTIC AND PREDICTIVE 189
    • 13.3.1 INSTRUMENT BASED PRODUCTS 190
    • 13.3.2 PLATFORM BASED PRODUCTS 190
    • 13.3.3 KITS AND REAGENTS 190
    • 13.3.4 OTHER CONSUMABLES 190
  • 13.4 PROGNOSTIC 191
    • 13.4.1 INSTRUMENT BASED PRODUCTS 192
    • 13.4.2 PLATFORM BASED PRODUCTS 192
    • 13.4.3 KITS AND REAGENTS 192
    • 13.4.4 OTHER CONSUMABLES 192
  • 13.5 RESEARCH 192
    • 13.5.1 INSTRUMENT BASED PRODUCTS 193
    • 13.5.2 PLATFORM BASED PRODUCTS 193
    • 13.5.3 KITS AND REAGENTS 193
    • 13.5.4 OTHER CONSUMABLES 194

14 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER 195

  • 14.1 OVERVIEW 196
  • 14.2 HOSPITALS 199
  • 14.3 DIAGNOSTIC CENTERS 199
  • 14.4 CANCER RESEARCH CENTERS 200
  • 14.5 ACADEMIC INSTITUTES 201
  • 14.6 AMBULATORY SURGICAL CENTERS 201
  • 14.7 OTHERS 202

15 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 203

  • 15.1 OVERVIEW 204
  • 15.2 DIRECT TENDER 207
  • 15.3 RETAIL SALES 207
  • 15.4 OTHERS 208

16 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION 209

  • 16.1 OVERVIEW 210
  • 16.2 NORTH AMERICA 216
    • 16.2.1 U.S. 230
    • 16.2.2 CANADA 239
    • 16.2.3 MEXICO 248
  • 16.3 ASIA-PACIFIC 257
    • 16.3.1 CHINA 270
    • 16.3.2 JAPAN 277
    • 16.3.3 INDIA 284
    • 16.3.4 SOUTH KOREA 291
    • 16.3.5 AUSTRALIA 298
    • 16.3.6 TAIWAN 305
    • 16.3.7 NEW ZEALAND 313
    • 16.3.8 INDONESIA 320
    • 16.3.9 THAILAND 327
    • 16.3.10 PHILIPPINES 334
    • 16.3.11 MALAYSIA 341
    • 16.3.12 VIETNAM 348
    • 16.3.13 SINGAPORE 355
    • 16.3.14 REST OF ASIA PACIFIC 362
  • 16.4 EUROPE 363
    • 16.4.1 GERMANY 379
    • 16.4.2 FRANCE 388
    • 16.4.3 UNITED KINGDOM 397
    • 16.4.4 ITALY 406
    • 16.4.5 SPAIN 415
    • 16.4.6 RUSSIA 424
    • 16.4.7 NETHERLANDS 433
    • 16.4.8 POLAND 442
    • 16.4.9 SWITZERLAND 451
    • 16.4.10 BELGIUM 460
    • 16.4.11 SWEDEN 469
    • 16.4.12 NORWAY 478
    • 16.4.13 DENMARK 487
    • 16.4.14 FINLAND 496
    • 16.4.15 TURKEY 505
    • 16.4.16 REST OF EUROPE 514
  • 16.5 SOUTH AMERICA 515
    • 16.5.1 BRAZIL 527
    • 16.5.2 ARGENTINA 534
    • 16.5.3 REST OF SOUTH AMERICA 542
  • 16.6 MIDDLE EAST AND AFRICA 543
    • 16.6.1 SOUTH AFRICA 556
    • 16.6.2 SAUDI ARABIA 563
    • 16.6.3 BAHRAIN 571
    • 16.6.4 U.A.E. 578
    • 16.6.5 EGYPT 586
    • 16.6.6 ISRAEL 594
    • 16.6.7 KUWAIT 602
    • 16.6.8 OMAN 610
    • 16.6.9 QATAR 618
    • 16.6.10 REST OF MIDDLE EAST AND AFRICA 626

17 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 627

  • 17.1 COMPANY SHARE ANALYSIS: GLOBAL 627
  • 17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 628
  • 17.3 COMPANY SHARE ANALYSIS: EUROPE 629
  • 17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 630

18 SWOT ANALYSIS 631

19 COMPANY PROFILE 632

  • 19.1 CANON MEDICAL SYSTEMS CORPORATION 632
    • 19.1.1 COMPANY SNAPSHOT 632
    • 19.1.2 REVENUE ANALYSIS 632
    • 19.1.3 COMPANY PROFILE 633
    • 19.1.4 PRODUCT PORTFOLIO 633
    • 19.1.5 RECENT DEVELOPMENT 633
  • 19.2 KONINKLIJKE PHILIPS N.V. 634
    • 19.2.1 COMPANY SNAPSHOT 634
    • 19.2.2 REVENUE ANALYSIS 634
    • 19.2.3 COMPANY PROFILE 635
    • 19.2.4 PRODUCT PORTFOLIO 635
    • 19.2.5 RECENT DEVELOPMENTS 636
  • 19.3 GENERAL ELECTRIC COMPANY 637
    • 19.3.1 COMPANY SNAPSHOT 637
    • 19.3.2 REVENUE ANALYSIS 637
    • 19.3.3 COMPANY PROFILE 638
    • 19.3.4 PRODUCT PORTFOLIO 638
    • 19.3.5 RECENT DEVELOPMENTS 639
  • 19.4 SIEMENS HEALTHCARE GMBH 640
    • 19.4.1 COMPANY SNAPSHOT 640
    • 19.4.2 REVENUE ANALYSIS 640
    • 19.4.3 COMPANY PROFILE 641
    • 19.4.4 PRODUCT PORTFOLIO 641
    • 19.4.5 RECENT DEVELOPMENT 642
  • 19.5 GRAIL 643
    • 19.5.1 COMPANY SNAPSHOT 643
    • 19.5.2 PRODUCT PORTFOLIO 643
    • 19.5.3 RECENT DEVELOPMENTS 643
  • 19.6 AMBRY GENETICS 645
    • 19.6.1 COMPANY SNAPSHOT 645
    • 19.6.2 PRODUCT PORTFOLIO 645
    • 19.6.3 RECENT DEVELOPMENT 645
Show more
  • 19.7 BIOVENDOR R&D 646
    • 19.7.1 COMPANY SNAPSHOT 646
    • 19.7.2 PRODUCT PORTFOLIO 646
    • 19.7.3 RECENT DEVELOPMENT 646
  • 19.8 BLUEPRINT GENETICS OY. 647
    • 19.8.1 COMPANY SNAPSHOT 647
    • 19.8.2 PRODUCT PORTFOLIO 647
    • 19.8.3 RECENT DEVELOPMENT 647
  • 19.9 CD GENOMICS 648
    • 19.9.1 COMPANY SNAPSHOT 648
    • 19.9.2 PRODUCT PORTFOLIO 648
    • 19.9.3 RECENT DEVELOPMENT 648
  • 19.10 CENTOGENE N.V. 649
    • 19.10.1 COMPANY SNAPSHOT 649
    • 19.10.2 REVENUE ANALYSIS 649
    • 19.10.3 PRODUCT PORTFOLIO 650
    • 19.10.4 RECENT DEVELOPMENT 650
  • 19.11 CREATIVE DIAGNOSTICS 651
    • 19.11.1 COMPANY SNAPSHOT 651
    • 19.11.2 PRODUCT PORTFOLIO 651
    • 19.11.3 RECENT DEVELOPMENT 651
  • 19.12 FUJIFILM CORPORATION 652
    • 19.12.1 COMPANY SNAPSHOT 652
    • 19.12.2 REVENUE ANALYSIS 652
    • 19.12.3 PRODUCT PORTFOLIO 653
    • 19.12.4 RECENT DEVELOPMENTS 653
  • 19.13 GENEDX, LLC 654
    • 19.13.1 COMPANY SNAPSHOT 654
    • 19.13.2 REVENUE ANALYSIS 654
    • 19.13.3 PRODUCT PORTFOLIO 655
    • 19.13.4 RECENT DEVELOPMENT 655
  • 19.14 GENPATH, A DIVISION OF BIOREFERENCE LABORATORIES, AN OPKO HEALTH INC. COMPANY 656
    • 19.14.1 COMPANY SNAPSHOT 656
    • 19.14.2 PRODUCT PORTFOLIO 656
    • 19.14.3 RECENT DEVELOPMENT 656
  • 19.15 ILLUMINA, INC. 657
    • 19.15.1 COMPANY SNAPSHOT 657
    • 19.15.2 REVENUE ANALYSIS 657
    • 19.15.3 PRODUCT PORTFOLIO 658
    • 19.15.4 RECENT DEVELOPMENT 658
  • 19.16 INVITAE CORPORATION 659
    • 19.16.1 COMPANY SNAPSHOT 659
    • 19.16.2 REVENUE ANALYSIS 659
    • 19.16.3 PRODUCT PORTFOLIO 660
    • 19.16.4 RECENT DEVELOPMENT 660
  • 19.17 LABORATORY CORPORATION OF AMERICA HOLDINGS 661
    • 19.17.1 COMPANY SNAPSHOT 661
    • 19.17.2 REVENUE ANALYSIS 661
    • 19.17.3 PRODUCT PORTFOLIO 662
    • 19.17.4 RECENT DEVELOPMENTS 662
  • 19.18 MYRIAD GENETICS, INC. 663
    • 19.18.1 COMPANY SNAPSHOT 663
    • 19.18.2 REVENUE ANALYSIS 663
    • 19.18.3 PRODUCT PORTFOLIO 664
    • 19.18.4 RECENT DEVELOPMENT 664
  • 19.19 THERMO FISHER SCIENTIFIC INC. 665
    • 19.19.1 COMPANY SNAPSHOT 665
    • 19.19.2 REVENUE ANALYSIS 665
    • 19.19.3 PRODUCT PORTFOLIO 666
    • 19.19.4 RECENT DEVELOPMENT 666
  • 19.20 QIAGEN 667
    • 19.20.1 COMPANY SNAPSHOT 667
    • 19.20.2 REVENUE ANALYSIS 667
    • 19.20.3 PRODUCT PORTFOLIO 668
    • 19.20.4 RECENT DEVELOPMENT 668

20 QUESTIONNAIRE 669

21 RELATED REPORTS 673

LIST OF TABLES

  • TABLE 1 ESTIMATED NEW CANCER CASES AND DEATHS 122
  • TABLE 2 APPROVED DIAGNOSTICS OF KIDNEY CANCER 124
  • TABLE 3 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 135
  • TABLE 4 GLOBAL IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 136
  • TABLE 5 GLOBAL IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 137
  • TABLE 6 GLOBAL BLOOD TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 138
  • TABLE 7 GLOBAL BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 139
  • TABLE 8 GLOBAL BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 139
  • TABLE 9 GLOBAL BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 140
  • TABLE 10 GLOBAL BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 141
  • TABLE 11 GLOBAL GENETIC TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 142
  • TABLE 12 GLOBAL OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 143
  • TABLE 13 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 147
  • TABLE 14 GLOBAL STAGE I IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 148
  • TABLE 15 GLOBAL STAGE II IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 149
  • TABLE 16 GLOBAL STAGE III IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 149
  • TABLE 17 GLOBAL STAGE IV IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 150
  • TABLE 18 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 155
  • TABLE 19 GLOBAL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 156
  • TABLE 20 GLOBAL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 157
  • TABLE 21 GLOBAL CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 158
  • TABLE 22 GLOBAL CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 158
  • TABLE 23 GLOBAL NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 160
  • TABLE 24 GLOBAL NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 160
  • TABLE 25 GLOBAL PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 160
  • TABLE 26 GLOBAL CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 161
  • TABLE 27 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 167
  • TABLE 28 GLOBAL INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 168
  • TABLE 29 GLOBAL INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 169
  • TABLE 30 GLOBAL INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 169
  • TABLE 31 GLOBAL INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 169
  • TABLE 32 GLOBAL PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 170
  • TABLE 33 GLOBAL PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 171
  • TABLE 34 GLOBAL PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 171
  • TABLE 35 GLOBAL PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 171
  • TABLE 36 GLOBAL KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 173
  • TABLE 37 GLOBAL KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 173
  • TABLE 38 GLOBAL KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 173
  • TABLE 39 GLOBAL KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 173
  • TABLE 40 GLOBAL OTHER CONSUMABLES IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 174
  • TABLE 41 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 178
  • TABLE 42 GLOBAL FLUORESCENT IN SITU HYBRIDIZATION IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 179
  • TABLE 43 GLOBAL NEXT GENERATION SEQUENCING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 180
  • TABLE 44 GLOBAL FLUORIMMUNOASSAY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 181
  • TABLE 45 GLOBAL COMPARATIVE GENOMIC HYBRIDIZATION IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 181
  • TABLE 46 GLOBAL IMMUNOHISTOCHEMICAL IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 182
  • TABLE 47 GLOBAL OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 183
  • TABLE 48 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 187
  • TABLE 49 GLOBAL SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 188
  • TABLE 50 GLOBAL SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 188
  • TABLE 51 GLOBAL DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 190
  • TABLE 52 GLOBAL DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 190
  • TABLE 53 GLOBAL PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 191
  • TABLE 54 GLOBAL PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 191
  • TABLE 55 GLOBAL RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 193
  • TABLE 56 GLOBAL RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 193
  • TABLE 57 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 198
  • TABLE 58 GLOBAL HOSPITALS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 199
  • TABLE 59 GLOBAL DIAGNOSTIC CENTERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 200
  • TABLE 60 GLOBAL CANCER RESEARCH CENTERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 200
  • TABLE 61 GLOBAL ACADEMIC INSTITUTES IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 201
  • TABLE 62 GLOBAL AMBULATORY SURGICAL CENTERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 202
  • TABLE 63 GLOBAL OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 202
  • TABLE 64 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 206
  • TABLE 65 GLOBAL DIRECT TENDER IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 207
  • TABLE 66 GLOBAL RETAIL SALES IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 208
  • TABLE 67 GLOBAL OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 208
  • TABLE 68 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 215
  • TABLE 69 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 221
  • TABLE 70 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 221
  • TABLE 71 NORTH AMERICA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 221
  • TABLE 72 NORTH AMERICA BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 222
  • TABLE 73 NORTH AMERICA BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 222
  • TABLE 74 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 222
  • TABLE 75 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 222
  • TABLE 76 NORTH AMERICA RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 223
  • TABLE 77 NORTH AMERICA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 223
  • TABLE 78 NORTH AMERICA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 223
  • TABLE 79 NORTH AMERICA PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 224
  • TABLE 80 NORTH AMERICA CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 224
  • TABLE 81 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 224
  • TABLE 82 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 225
  • TABLE 83 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 225
  • TABLE 84 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 225
  • TABLE 85 NORTH AMERICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 225
  • TABLE 86 NORTH AMERICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 226
  • TABLE 87 NORTH AMERICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 226
  • TABLE 88 NORTH AMERICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 226
  • TABLE 89 NORTH AMERICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 227
  • TABLE 90 NORTH AMERICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 227
  • TABLE 91 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 227
  • TABLE 92 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 227
  • TABLE 93 NORTH AMERICA SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 228
  • TABLE 94 NORTH AMERICA DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 228
  • TABLE 95 NORTH AMERICA PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 228
  • TABLE 96 NORTH AMERICA RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 229
  • TABLE 97 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 229
  • TABLE 98 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 229
  • TABLE 99 U.S. KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 230
  • TABLE 100 U.S. IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 230
  • TABLE 101 U.S. BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 230
  • TABLE 102 U.S. BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 231
  • TABLE 103 U.S. KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 231
  • TABLE 104 U.S. KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 231
  • TABLE 105 U.S. RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 232
  • TABLE 106 U.S. CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 232
  • TABLE 107 U.S. NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 232
  • TABLE 108 U.S. PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 233
  • TABLE 109 U.S. CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 233
  • TABLE 110 U.S. KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 233
  • TABLE 111 U.S. INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 234
  • TABLE 112 U.S. INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 234
  • TABLE 113 U.S. INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 234
  • TABLE 114 U.S. PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 234
  • TABLE 115 U.S. PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 235
  • TABLE 116 U.S. PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 235
  • TABLE 117 U.S. KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 235
  • TABLE 118 U.S. KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 235
  • TABLE 119 U.S. KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 235
  • TABLE 120 U.S. KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 236
  • TABLE 121 U.S. KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 236
  • TABLE 122 U.S. SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 236
  • TABLE 123 U.S. DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 237
  • TABLE 124 U.S. PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 237
  • TABLE 125 U.S. RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 237
  • TABLE 126 U.S. KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 238
  • TABLE 127 U.S. KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 238
  • TABLE 128 CANADA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 239
  • TABLE 129 CANADA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 239
  • TABLE 130 CANADA BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 239
  • TABLE 131 CANADA BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 240
  • TABLE 132 CANADA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 240
  • TABLE 133 CANADA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 240
  • TABLE 134 CANADA RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 241
  • TABLE 135 CANADA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 241
  • TABLE 136 CANADA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 241
  • TABLE 137 CANADA PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 242
  • TABLE 138 CANADA CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 242
  • TABLE 139 CANADA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 242
  • TABLE 140 CANADA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 243
  • TABLE 141 CANADA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 243
  • TABLE 142 CANADA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 243
  • TABLE 143 CANADA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 243
  • TABLE 144 CANADA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 244
  • TABLE 145 CANADA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 244
  • TABLE 146 CANADA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 244
  • TABLE 147 CANADA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 244
  • TABLE 148 CANADA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 244
  • TABLE 149 CANADA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 245
  • TABLE 150 CANADA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 245
  • TABLE 151 CANADA SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 245
  • TABLE 152 CANADA DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 246
  • TABLE 153 CANADA PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 246
  • TABLE 154 CANADA RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 246
  • TABLE 155 CANADA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 247
  • TABLE 156 CANADA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 247
  • TABLE 157 MEXICO KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 248
  • TABLE 158 MEXICO IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 248
  • TABLE 159 MEXICO BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 248
  • TABLE 160 MEXICO BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 249
  • TABLE 161 MEXICO KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 249
  • TABLE 162 MEXICO KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 249
  • TABLE 163 MEXICO RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 250
  • TABLE 164 MEXICO CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 250
  • TABLE 165 MEXICO NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 250
  • TABLE 166 MEXICO PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 251
  • TABLE 167 MEXICO CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 251
  • TABLE 168 MEXICO KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 251
  • TABLE 169 MEXICO INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 252

LIST OF FIGURES

  • FIGURE 1 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET: SEGMENTATION 92
  • FIGURE 2 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION 95
  • FIGURE 3 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET: DROC ANALYSIS 96
  • FIGURE 4 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 97
  • FIGURE 5 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 97
  • FIGURE 6 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 98
  • FIGURE 7 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID 100
  • FIGURE 8 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 102
  • FIGURE 9 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 103
  • FIGURE 10 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET: SEGMENTATION 107
  • FIGURE 11 GROWING AWARENESS OF KIDNEY CANCER AND INCREASING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE GROWTH OF THE GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030 108
  • FIGURE 12 THE IMAGING TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET IN 2023 & 2030 108
  • FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET, AND NORTH AMERICA IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030 109
  • FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR KIDNEY CANCER DIAGNOSTIC MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030 110
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET 121
  • FIGURE 16 KIDNEY CANCER INCIDENCE, BOTH SEXES, BY REGION (2020) 123
  • FIGURE 17 KIDNEY CANCER MORTALITY, BOTH SEXES, BY REGION (2020) 123
  • FIGURE 18 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2022 133
  • FIGURE 19 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2023-2030 (USD MILLION) 134
  • FIGURE 20 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, CAGR (2023-2030) 134
  • FIGURE 21 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, LIFELINE CURVE 135
  • FIGURE 22 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE , 2022 145
  • FIGURE 23 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE, 2023-2030 (USD MILLION) 146
  • FIGURE 24 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE, CAGR (2023-2030) 146
  • FIGURE 25 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE, LIFELINE CURVE 147
  • FIGURE 26 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, 2022 153
  • FIGURE 27 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, 2023-2030 (USD MILLION) 154
  • FIGURE 28 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, CAGR (2023-2030) 154
  • FIGURE 29 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, LIFELINE CURVE 155
  • FIGURE 30 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, 2022 165
  • FIGURE 31 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, 2023-2030 (USD MILLION) 166
  • FIGURE 32 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, CAGR (2023-2030) 166
  • FIGURE 33 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, LIFELINE CURVE 167
  • FIGURE 34 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, 2022 176
  • FIGURE 35 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, 2023-2030 (USD MILLION) 177
  • FIGURE 36 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, CAGR (2023-2030) 177
  • FIGURE 37 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, LIFELINE CURVE 178
  • FIGURE 38 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, 2022 185
  • FIGURE 39 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, 2023-2030 (USD MILLION) 186
  • FIGURE 40 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, CAGR (2023-2030) 186
  • FIGURE 41 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, LIFELINE CURVE 187
  • FIGURE 42 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, 2022 196
  • FIGURE 43 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, 2023-2030 (USD MILLION) 197
  • FIGURE 44 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, CAGR (2023-2030) 197
  • FIGURE 45 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE 198
  • FIGURE 46 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2022 204
  • FIGURE 47 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 205
  • FIGURE 48 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 205
  • FIGURE 49 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE 206
  • FIGURE 50 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 211
  • FIGURE 51 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET: BY REGION (2022) 213
  • FIGURE 52 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET: BY REGION (2023 & 2030) 213
  • FIGURE 53 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET: BY REGION (2022 & 2030) 214
  • FIGURE 54 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET: BY TEST TYPE (2023 - 2030) 214
  • FIGURE 55 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 217
  • FIGURE 56 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 219
  • FIGURE 57 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 219
  • FIGURE 58 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 220
  • FIGURE 59 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 220
  • FIGURE 60 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 258
  • FIGURE 61 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 260
  • FIGURE 62 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 260
  • FIGURE 63 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 261
  • FIGURE 64 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 261
  • FIGURE 65 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 364
  • FIGURE 66 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 366
  • FIGURE 67 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 366
  • FIGURE 68 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 367
  • FIGURE 69 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 368
  • FIGURE 70 SOUTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 516
  • FIGURE 71 SOUTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 518
  • FIGURE 72 SOUTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 518
  • FIGURE 73 SOUTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 519
  • FIGURE 74 SOUTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 519
  • FIGURE 75 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 544
  • FIGURE 76 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 546
  • FIGURE 77 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 546
  • FIGURE 78 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 547
  • FIGURE 79 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 547
  • FIGURE 80 GLOBAL KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 627
  • FIGURE 81 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 628
  • FIGURE 82 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 629
  • FIGURE 83 ASIA-PACIFIC KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 630
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!